Targeted drug duo teams up with radiation to fight stubborn thyroid cancer
NCT ID NCT03244956
Summary
This study tested whether adding two targeted drugs (trametinib and dabrafenib) could help radioactive iodine work again for people with advanced thyroid cancer that had specific genetic mutations (RAS or BRAFV600E). It involved 40 adults whose cancer had spread and was no longer responding to standard radioactive iodine treatment. The goal was to see if this drug combination could shrink tumors and control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.